Your session is about to expire
← Back to Search
JNJ-64264681 for Non-Hodgkin's Lymphoma and Leukemia
Study Summary
This trial is testing a new drug to treat B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Researchers will determine the best dosage of the drug and then study how safe it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I haven't taken any experimental drugs or vaccines within the last 2 weeks or five half-lives before starting the study drug.My cancer has spread to my brain or spinal cord.I am allergic to JNJ-64264681 or its ingredients.I still have side effects from cancer treatment, except for hair loss or nerve issues.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: JNJ-64264681: Dose Escalation and Expansion
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the aspirations of this clinical research endeavor?
"The primary outcome of this clinical trial will be tracked over a span of up to 21 days and consists in the number of participants who experience adverse events (AEs). Secondary outcomes include blood concentrations of JNJ-64264681, percentage occupancy on target cells, as well as an overall response rate based on criteria established by the Revised Response Criteria for Malignant Lymphoma and International Workshops on Chronic lymphocytic leukemia (iwCLL) Response Criteria and International Workshop for Waldenstrom Macroglobulinemia (IWWM) Response Criteria."
Are participants still being accepted to take part in this medical experiment?
"The medical trial is open to applicants, with information regarding its initial posting on July 2nd of 2020 and the most recent update from November 3rd 2022 available via clinicaltrials.gov."
What is the cap on participant enrollment for this clinical trial?
"Affirmative. Data hosted on clinicaltrials.gov affirms that this medical study, which was first posted on July 2nd 2020, is actively recruiting. Approximately 108 participants need to be enrolled from just 1 site."
What is the safety profile of JNJ-64264681 for patients?
"Due to the scarcity of data supporting the efficacy and safety of JNJ-64264681, it was assigned a score of 1."
Share this study with friends
Copy Link
Messenger